-
公开(公告)号：US20140322208A1
公开(公告)日：2014-10-30
申请号：US14356996
申请日：2012-11-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michelle R. Kuhne , Chin Pan , Josephine M. Cardarelli
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2866 , A61K31/136 , A61K31/4184 , A61K31/454 , A61K31/555 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/7048 , A61K31/7068 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , A61K2300/00
Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
Abstract translation: 本公开提供以高亲和力特异性结合CXCR4的人单克隆抗体。 该公开内容还提供了治疗患有表达CXCR4的癌症，特别是诸如多发性骨髓瘤，急性骨髓性白血病或非霍奇金淋巴瘤的血液恶性肿瘤的受试者的方法，其包括向受试者施用治疗有效量的药物 组合物，其包含本公开的抗CXCR4抗体。 本公开还提供了用于治疗受试者中的癌症的试剂盒，其包含抗CXCR4抗体的剂量和在本公开的治疗方法中使用抗CXCR4抗体的说明书。
-
公开(公告)号：US10428151B2
公开(公告)日：2019-10-01
申请号：US14356996
申请日：2012-11-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michelle R. Kuhne , Chin Pan , Josephine M. Cardarelli
IPC: C07K16/28 , A61K31/454 , A61K31/69 , A61K31/136 , A61K31/4184 , A61K31/555 , A61K31/573 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K39/395 , A61K39/00 , A61K45/06
Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
-
Patent Agency Ranking
3.发明授权Immunoconjugates, compositions for making them, and methods of making and use 有权免疫缀合物，制备它们的组合物，以及制备和使用方法公开(公告)号：US09186416B2
公开(公告)日：2015-11-17
申请号：US14471096
申请日：2014-08-28
Applicant: Bristol-Myers Squibb Company
Inventor： Qian Zhang , Sanjeev Gangwar , Chin Pan , Daniel W. Derwin
IPC: A61K47/48 , C07K5/06 , C07K5/10 , C07K5/08 , A61K31/404 , C07D403/06 , C07D403/14 , C07D209/60
CPC classification number: A61K47/48384 , A61K31/404 , A61K47/6803 , A61K47/6851 , A61K47/6857 , A61K47/6859 , A61K47/6863 , A61K47/6869 , C07D209/60 , C07D403/06 , C07D403/14 , C07K5/06 , C07K5/06034 , C07K5/06095 , C07K5/08 , C07K5/0808 , C07K5/10
Abstract: An immunoconjugate in which a phosphate-prodrugged DNA minor groove binding agent of formula (I), where X is a nucleophilically displaceable leaving group, is conjugated to an antibody or an antigen binding fragment of an antibody, and compounds that can be used for making such immunoconjugates, and uses of such immunoconjugates.
Abstract translation: 一种免疫偶联物，其中式（I）的磷酸酯前体化DNA小沟结合剂（其中X是可亲可取代的离去基团）与抗体或抗体的抗原结合片段缀合，以及可用于制备的化合物 这样的免疫缀合物，以及这种免疫缀合物的用途。
-
4.发明申请IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE 有权免疫球蛋白，制备它们的组合物，制备和使用方法公开(公告)号：US20140364585A1
公开(公告)日：2014-12-11
申请号：US14471096
申请日：2014-08-28
Applicant: Bristol-Myers Squibb Company
Inventor： Qian ZHANG , Sanjeev Gangwar , Chin Pan , Daniel W. Derwin
IPC: A61K47/48 , A61K31/404 , C07K5/08 , C07K5/06 , C07K5/10
CPC classification number: A61K47/48384 , A61K31/404 , A61K47/6803 , A61K47/6851 , A61K47/6857 , A61K47/6859 , A61K47/6863 , A61K47/6869 , C07D209/60 , C07D403/06 , C07D403/14 , C07K5/06 , C07K5/06034 , C07K5/06095 , C07K5/08 , C07K5/0808 , C07K5/10
Abstract: An immunoconjugate in which a phosphate-prodrugged DNA minor groove binding agent of formula (I), where X is a nucleophilically displaceable leaving group, is conjugated to an antibody or an antigen binding fragment of an antibody, and compounds that can be used for making such immunoconjugates, and uses of such immunoconjugates.
Abstract translation: 一种免疫偶联物，其中式（I）的磷酸酯前体化DNA小沟结合剂（其中X是可亲可取代的离去基团）与抗体或抗体的抗原结合片段缀合，以及可用于制备的化合物 这样的免疫缀合物，以及这种免疫缀合物的用途。
-
公开(公告)号：US11104739B2
公开(公告)日：2021-08-31
申请号：US16093288
申请日：2017-04-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Josephine M. Cardarelli , Daniel E. Lopes de Menezes , Paul D. Ponath , Bingliang Chen , Chin Pan
IPC: C07K16/28 , A61K39/395 , C07K16/30 , A61K47/68 , A61P35/00
Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
-
公开(公告)号：US20200231683A1
公开(公告)日：2020-07-23
申请号：US16590152
申请日：2019-10-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： MICHELLE R. KUHNE , Chin Pan , Josephine M. Cardarelli
IPC: C07K16/28 , A61K45/06 , A61K31/136 , A61K31/4184 , A61K31/454 , A61K31/555 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/7048 , A61K31/7068 , A61K39/395
Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
-
公开(公告)号：US20180179282A1
公开(公告)日：2018-06-28
申请号：US15735055
申请日：2016-06-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Josephine M. Cardarelli , Wendy L. Clemens , Glenn S. Kroog , Daniel E. Lopes de Menezes , Chin Pan , Paul D. Ponath , Jean Viallet
CPC classification number: C07K16/2818 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61P35/00 , C07K16/24 , C07K16/2827 , C07K16/2866 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/76
Abstract: This disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a combination of therapeutically effective amounts of an antibody or an antigen-binding portion thereof that binds specifically to Programmed Death-1 (PD-1) or to Programmed Death Ligand-1 (PD-L1), and an antibody or an antigen-binding portion thereof that binds specifically to C-X-C Chemokine Receptor 4 (CXCR4) or to C-X-C motif chemokine 12 (CXCL12). The disclosure also provides a kit for treating a subject afflicted with a cancer, the kit comprising one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to PD-1 or to PD-L1, one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to CXCR4 or to CXCL12, and instructions for using the antibodies or portions thereof for treating the subject.
-
-
-
-
-
-
Search Results
7
records
(took 0.061 seconds)
